Evidence map›Paper›PMID 16462763›Full record

ArticleOncogene2006

Identification of vitamin D receptor as a target of p63.

R Kommagani, T M Caserta, M P Kadakia

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Vitamin D receptor cross-talk with p63 signaling promotes epidermal cell fate.The Journal of steroid biochemistry and molecular biology · 2023
    Article
  3. Role of vitamin D and calcium signaling in epidermal wound healing.Journal of endocrinological investigation · 2023
    Review
  4. p63-related signaling at a glance.Journal of cell science · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Vitamin D receptor and RXR in the post-genomic era.Journal of cellular physiology · 2015
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

R KommaganiDepartment of Biochemistry and Molecular Biology, Dayton, OH 45435, USA.
T M Caserta
M P Kadakia
Wright State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

p63, a p53 homolog has been shown to play a role in development and cancer. p63 is essential for both commitment of ectoderm to stratified epithelia and for the proliferative potential of epithelial stem cells. p63 knockout mice are born with severe development defects and lack organs of epithelial origin. In addition, p63 has also been shown to play a role in cancer development through the differential regulation of genes with tumor suppressor function and genes involved in metastasis. In order to understand the role of p63 in cancer and development, genes that are specifically regulated by p63 but not p53 were identified. In this study, we provide evidence that p63gamma specifically upregulates vitamin D Receptor (VDR). In contrast, p53 does not appear to be involved in upregulation of VDR expression. Additionally, we demonstrate that a naturally occurring p63 missense mutant, p63gamma (R279H) and p14(ARF), both act in a dominant negative manner to inhibit p63gamma-mediated upregulation of VDR. Furthermore, using chromatin immunoprecipitation assays, we demonstrated that p63 directly binds to the VDR promoter in vivo. Our findings clearly demonstrate that VDR is a direct target of p63 and suggests that p63 may play a role in cancer and differentiation through modulation of the VDR pathway.

Indexed as

Bone NeoplasmsCell DifferentiationChromatin ImmunoprecipitationDNA-Binding ProteinsGene Expression RegulationHeLa CellsHumansMutation, MissenseOsteosarcomaPromoter Regions, GeneticReceptors, CalcitriolResponse ElementsTrans-ActivatorsTranscription FactorsTumor Cells, CulturedTumor Suppressor Protein p14ARFDNA-Binding ProteinsReceptors, CalcitriolTP63 protein, humanTrans-ActivatorsTranscription FactorsTumor Suppressor Protein p14ARFTumor Suppressor Proteins

Identifiers

PMID16462763
OpenAlexW2030321647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.